Andrew Feigin

Best Publications

• Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

  Michael G Kaplitt;Andrew Feigin;Andrew Feigin;Chengke Tang;Helen L Fitzsimons

  1306
  Citations

• AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

  Peter A LeWitt;Ali R Rezai;Maureen A Leehey;Steven G Ojemann

  750
  Citations

• FDG PET in the differential diagnosis of parkinsonian disorders

  Thomas Eckert;Anna Barnes;Vijay Dhawan;Vijay Dhawan;Vijay Dhawan;Steve Frucht

  489
  Citations

• Changes in network activity with the progression of Parkinson's disease.

  Chaorui Huang;Chengke Tang;Andrew Feigin;Martin Lesser

  451
  Citations

• Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis

  Chris C Tang;Kathleen L Poston;Kathleen L Poston;Kathleen L Poston;Thomas Eckert;Thomas Eckert;Andrew Feigin

  409
  Citations

• The role of radiotracer imaging in Parkinson disease

  B. Ravina;D. Eidelberg;J. E. Ahlskog;R. L. Albin

  385
  Citations

• Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

  S. M. Hersch;S. Gevorkian;K. Marder;C. Moskowitz

  374
  Citations

• A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit

  M Flint Beal;David Oakes;Ira Shoulson

  344
  Citations

• Dyskinesia after fetal cell transplantation for parkinsonism: a PET study.

  Yilong Ma;Yilong Ma;Andrew Feigin;Andrew Feigin;Vijay Dhawan;Vijay Dhawan;Masafumi Fukuda

  303
  Citations

• Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease

  Andrew Feigin;Michael G. Kaplitt;Chengke Tang;Tanya Lin

  282
  Citations

• Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial

  Samuel Frank;Claudia M. Testa;David Stamler;Elise Kayson

  243
  Citations

• An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease

  Dennis J. Zgaljardic;Joan C. Borod;Nancy S. Foldi;Paul J. Mattis

  241
  Citations

• Metabolic correlates of levodopa response in Parkinson's disease.

  A. Feigin;M. Fukuda;V. Dhawan;S. Przedborski

  231
  Citations

• Metabolic Network Abnormalities in Early Huntington’s Disease: An [18F]FDG PET Study

  Andrew Feigin;Klaus L. Leenders;James R. Moeller;John Missimer

  224
  Citations

• The metabolic anatomy of Tourette's syndrome.

  D. Eidelberg;J. R. Moeller;A. Antonini;K. Kazumata

  224
  Citations

• Thalamic metabolism and symptom onset in preclinical Huntington's disease.

  A. Feigin;C. Tang;Y. Ma;P. Mattis

  223
  Citations

• Abnormal metabolic networks in atypical parkinsonism.

  Thomas Eckert;Thomas Eckert;Chengke Tang;Yilong Ma;Yilong Ma;Nathaniel Brown

  212
  Citations

• Trinucleotide repeat length and progression of illness in Huntington's disease.

  K Kieburtz;M MacDonald;C Shih;A Feigin

  195
  Citations

• Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT

  Robert B. Innis;Kenneth L. Marek;Kim Sheff;Sami Zoghbi

  181
  Citations

• Abnormal metabolic network activity in REM sleep behavior disorder

  Florian Holtbernd;Jean-François Gagnon;Ron B. Postuma;Yilong Ma

  178
  Citations